TGen Physician-in-Chief Dr. Daniel Von Hoff inducted today into Joshua Lederberg Society
(The Translational Genomics Research Institute) Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-in-Chief of the Translational Genomics Research Institute, will be inducted today into the Joshua Lederberg Society for his work in developing the drug Abraxane for advanced pancreatic cancer patients. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 13, 2014 Category: Biology Source Type: news
Drug offers new hope in pancreatic cancer battle: Treatment that can extend life by two months licensed for use in the UK
The drug, called Abraxane, is being hailed as the biggest advance in almost two decades against a disease that kills four in five sufferers within a year. (Source: the Mail online | Health)
Source: the Mail online | Health - February 6, 2014 Category: Consumer Health News Source Type: news
ABRAXANE® plus gemcitabine receives European Marketing Authorization for metastatic pancreatic cancerfor
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), has announced that the European Commission (EC) has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 15, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Oncology Latest News Source Type: news
OncoMed starts Phase Ib study of combination therapy in pancreatic cancer patients
OncoMed Pharmaceuticals has initiated a multi-centre Phase Ib clinical trial of its first-in-class Wnt-pathway-targeting decoy receptor OMP-54F28 (Fzd8-Fc) with nab-paclitaxel (Abraxane) and gemcitabine in pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - January 14, 2014 Category: Pharmaceuticals Source Type: news
Celgene receives European approval for ABRAXANE plus gemcitabine combination therapy for pancreatic cancer treatment
Switzerland-based Celgene International has received approval from the European Commission (EC) for ABRAXANE plus gemcitabine combination therapy for first-line treatment of adult patients with metastatic pancreatic cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 9, 2014 Category: Pharmaceuticals Source Type: news
UCLA researcher highlights advances in nanotechnology's fight against cancer
As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.
A new research review co-authored by a UCLA professor provides one of the most comprehensive assessments to date of research on nanomedicine-based approaches to treating cancer and offers insight into how researchers can best position nanomedicine-base...
Source: UCLA Newsroom: Health Sciences - December 18, 2013 Category: Universities & Medical Training Source Type: news
Novel Agent Set for Unique Clinical Test in Inflammatory Breast Cancer
A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center. The finding, published in a recent issue of the Journal of Experimental Therapeutics and Oncology, has led to development of a phase 1/2 clinical trial at Kimmel Cancer Center to test the agent, Romidepsin (Istodax™), in combination with nab-paclitaxel (Abraxane™) chemotherapy for advanced inflammatory breast cancer (IBC). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
OncoMed begins third Phase Ib combination therapy study of pancreatic cancer
OncoMed Pharmaceuticals has initiated a Phase Ib clinical trial of its Wnt-pathway-targeting antibody vantictumab (OMP-18R5) in combination with nab-paclitaxel (Abraxane) and gemcitabine in patients with Stage IV pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - December 6, 2013 Category: Pharmaceuticals Source Type: news
Positive CHMP opinion for ABRAXANE®
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), has announced that the European Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 25, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Oncology Latest News Source Type: news
Chemo Agents Equal in Treating Gastric Cancer (CME/CE)
(MedPage Today) -- Weekly paclitaxel (Abraxane) was as effective as biweekly irinotecan (Camptosar) as second-line therapy for advanced gastric cancer, researchers found. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 4, 2013 Category: Gastroenterology Source Type: news
UCLA faculty member's foundation gives $4 million to UC Global Health Institute
The Chan Soon-Shiong Family Foundation has donated $4 million to the University of California Global Health Institute to support new cross-campus and interdisciplinary education and research programs that aim to improve the health and well-being of vulnerable people and communities throughout California and across the globe.
The Los Angeles–based foundation was founded by Dr. Patrick Soon-Shiong, a UCLA faculty member, inventor and philanthropist, and his wife, Michele Chan, a television and film actress.
"Students are demanding a global education, and one mission of the Global Health Institute is to pr...
Source: UCLA Newsroom: Health Sciences - November 4, 2013 Category: Universities & Medical Training Source Type: news
Celgene profit tops Street view; raises 2013 forecast
(Reuters) - Celgene Corp on Thursday reported a slightly higher-than-expected third-quarter profit as sales of its flagship blood cancer drug Revlimid and of Abraxane for breast and lung cancer grew, and the company raised its 2013 earnings forecast. (Source: Reuters: Health)
Source: Reuters: Health - October 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Patients with advanced pancreatic cancer benefit from Abraxane (nab-paclitaxel)
By all measures, the addition of nab-paclitaxel for the treatment of patients with advanced pancreatic cancer was superior to the survival for patients who received only gemcitabine, according to the results of a study led by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, published by The New England Journal of Medicine... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 18, 2013 Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news
Nab-Paclitaxel Added to Gemcitabine Increases Survival in Metastatic Pancreatic Cancer (FREE)
By Joe Elia
Patients with metastatic cancer of the pancreas showed better overall survival on a regimen of gemcitabine plus albumin-bound paclitaxel than with gemcitabine alone, according to a New England Journal … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 17, 2013 Category: Primary Care Source Type: news
Abraxane for the Treatment of Late-Stage Pancreatic Cancer
Abraxane (albumin-bound paclitaxel for injectable suspension) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - September 15, 2013 Category: Pharmaceuticals Source Type: news
